View in EDS HTML Full Text PDF Full Text

Combination of PD-1 inhibitor with GVD (gemcitabine, vinorelbine, liposomal doxorubicin) versus GVD regimen as second-line therapy for relapsed/refractory classical Hodgkin lymphoma.

Saved in:
Bibliographic Details
Title: Combination of PD-1 inhibitor with GVD (gemcitabine, vinorelbine, liposomal doxorubicin) versus GVD regimen as second-line therapy for relapsed/refractory classical Hodgkin lymphoma.
Authors: Zhang YC; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China., Wang JN; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China., Ma SY; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China., Cai J; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China., Su N; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China., Huang HQ; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China., Li ZM; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China., Xia ZJ; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.; Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China., Huang H; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China., Liu PP; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China., Xia Y; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China., Cai QQ; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
Source: British journal of haematology [Br J Haematol] 2022 Jan; Vol. 196 (1), pp. 127-135. Date of Electronic Publication: 2021 Oct 07.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 34618912
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Combination of PD-1 inhibitor with GVD (gemcitabine, vinorelbine, liposomal doxorubicin) versus GVD regimen as second-line therapy for relapsed/refractory classical Hodgkin lymphoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Zhang+YC%22">Zhang YC</searchLink>; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.<br /><searchLink fieldCode="AU" term="%22Wang+JN%22">Wang JN</searchLink>; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.<br /><searchLink fieldCode="AU" term="%22Ma+SY%22">Ma SY</searchLink>; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.<br /><searchLink fieldCode="AU" term="%22Cai+J%22">Cai J</searchLink>; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.<br /><searchLink fieldCode="AU" term="%22Su+N%22">Su N</searchLink>; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.<br /><searchLink fieldCode="AU" term="%22Huang+HQ%22">Huang HQ</searchLink>; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.<br /><searchLink fieldCode="AU" term="%22Li+ZM%22">Li ZM</searchLink>; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.<br /><searchLink fieldCode="AU" term="%22Xia+ZJ%22">Xia ZJ</searchLink>; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.; Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.<br /><searchLink fieldCode="AU" term="%22Huang+H%22">Huang H</searchLink>; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.<br /><searchLink fieldCode="AU" term="%22Liu+PP%22">Liu PP</searchLink>; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.<br /><searchLink fieldCode="AU" term="%22Xia+Y%22">Xia Y</searchLink>; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.<br /><searchLink fieldCode="AU" term="%22Cai+QQ%22">Cai QQ</searchLink>; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220372544%22">British journal of haematology</searchLink> [Br J Haematol] 2022 Jan; Vol. 196 (1), pp. 127-135. <i>Date of Electronic Publication: </i>2021 Oct 07.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley-Blackwell%22">Wiley-Blackwell </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>0372544 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1365-2141 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200071048%22">00071048 </searchLink><i>NLM ISO Abbreviation: </i>Br J Haematol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34618912
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/bjh.17849
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 127
    Titles:
      – TitleFull: Combination of PD-1 inhibitor with GVD (gemcitabine, vinorelbine, liposomal doxorubicin) versus GVD regimen as second-line therapy for relapsed/refractory classical Hodgkin lymphoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Zhang YC
      – PersonEntity:
          Name:
            NameFull: Wang JN
      – PersonEntity:
          Name:
            NameFull: Ma SY
      – PersonEntity:
          Name:
            NameFull: Cai J
      – PersonEntity:
          Name:
            NameFull: Su N
      – PersonEntity:
          Name:
            NameFull: Huang HQ
      – PersonEntity:
          Name:
            NameFull: Li ZM
      – PersonEntity:
          Name:
            NameFull: Xia ZJ
      – PersonEntity:
          Name:
            NameFull: Huang H
      – PersonEntity:
          Name:
            NameFull: Liu PP
      – PersonEntity:
          Name:
            NameFull: Xia Y
      – PersonEntity:
          Name:
            NameFull: Cai QQ
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: 2022 Jan
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1365-2141
          Numbering:
            – Type: volume
              Value: 196
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: British journal of haematology
              Type: main
ResultId 1